Immunocore (NASDAQ:IMCR) Stock Price Down 4.7%

Shares of Immunocore Holdings plc (NASDAQ:IMCR) dropped 4.7% on Thursday . The company traded as low as $38.12 and last traded at $38.12. Approximately 407 shares changed hands during mid-day trading, a decline of 99% from the average daily volume of 55,135 shares. The stock had previously closed at $39.99.

Separately, Zacks Investment Research downgraded Immunocore from a “hold” rating to a “sell” rating in a report on Tuesday.

The company has a fifty day moving average price of $33.77 and a 200 day moving average price of $36.51. The company has a current ratio of 5.70, a quick ratio of 5.70 and a debt-to-equity ratio of 0.27.

Immunocore (NASDAQ:IMCR) last announced its earnings results on Wednesday, August 11th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.68) by ($0.36). The company had revenue of $7.92 million during the quarter, compared to the consensus estimate of $7.03 million. On average, sell-side analysts expect that Immunocore Holdings plc will post -4.28 EPS for the current year.

A number of hedge funds have recently bought and sold shares of the business. Baker BROS. Advisors LP purchased a new position in Immunocore in the first quarter worth $107,307,000. Rock Springs Capital Management LP purchased a new position in shares of Immunocore during the 1st quarter valued at $97,583,000. RTW Investments LP purchased a new position in shares of Immunocore during the 1st quarter valued at $50,142,000. BlackRock Inc. purchased a new position in shares of Immunocore during the 1st quarter valued at $45,981,000. Finally, General Atlantic LLC purchased a new position in shares of Immunocore during the 1st quarter valued at $40,442,000. 35.80% of the stock is currently owned by institutional investors and hedge funds.

About Immunocore (NASDAQ:IMCR)

Immunocore Holdings Limited, a late-stage biotechnology company, develops immunotherapies for the treatment of oncology, infectious, and autoimmune diseases. The company's lead oncology therapeutic candidate is tebentafusp, which is in a randomized Phase III clinical trial in patients with previously untreated metastatic uveal melanoma, a cancer that has historically proven to be insensitive to other immunotherapies.

Featured Article: Growth and Income Funds

Receive News & Ratings for Immunocore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunocore and related companies with MarketBeat.com's FREE daily email newsletter.